Dr. Ken He Young is an Associate Professor of Hematopathology Department at The University of Texas MD Anderson Cancer Center, Texas, USA. Dr. Ken received his MD (1984) from Zhejiang University School of Medicine, China and PhD (1995) from University of Lund School of Medicine, Sweden. Research in his team includes several types of hematologic malignancies, with special emphasis on pathogenesis of malignant lymphomas, especially diffuse large B-cell lymphoma (DLBCL). The goal of Dr. Ken's team is to explore and identify genetic and non-genetic biomarkers, including p53, Myc, pTEN, Mdm2, Arf, Bcl-2, Bcl-6 genes, alone or in combination with other abnormalities in DLBCL, that predict cancer prognosis and susceptibility. Dr. Ken's primary study of genomic alterations is on TP53 tumor suppressor pathway and secondary focus is on Myc oncogene.